Vimarsana
Biggest News Aggregation in the World

Page 18 - Manufacturing Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Manufacturing Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Manufacturing Program Today - Breaking & Trending Today

The PLI scheme is beginning to make India a manufacturing powerhouse - Vimarsana News

The PLI scheme is beginning to make India a manufacturing powerhouse

However, the industry must remember that the PLI scheme is for five years only, and it must use these five years to make Indian manufacturing globally competitive

In-depth: How Indian brands cracked the tough wearables market, ET Telecom - Vimarsana News

In-depth: How Indian brands cracked the tough wearables market, ET Telecom

Indian Wearable Brands: As per IDC, India-based smaller players who cumulatively hold >15% share are further lowering the overall average selling prices (ASPs). The ASP was at Rs 1,800 ($22.7) in 1Q23 compared to Rs 2,400 ($29.5) in 1Q22.

Community benches stolen at Buffalo Central Terminal - Vimarsana News

Community benches stolen at Buffalo Central Terminal

Two handmade community benches were reported stolen from the Buffalo Central Terminal's Great Lawn on Saturday.

Source: wgrz.com
PLI Schemes: 76% growth in manufacturing sector FDI, 20% value addition in mobile manufacturing in 3 yrs | Indiablooms - Vimarsana News

PLI Schemes: 76% growth in manufacturing sector FDI, 20% value addition in mobile manufacturing in 3 yrs | Indiablooms

New Delhi: The Production Linked Incentive (PLI) Schemes have led to a significant increase in production, employment generation, economic growth and exports in the country, a top government official said.

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough - Vimarsana News

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...